thymosin beta-4 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Antibiotic disks are used to test the ability for an antibiotic to inhibit growth of a microorganism. This method, which is commonly used with Mueller–Hinton agar, is used by evenly seeding bacteria over a petri dish and applying an antibiotic treated disk to the top of the agar. By observing the ring formed around the disk formed due to the lack of bacterial growth, the zone of inhibition can be found, which is used to find the susceptibility of an organism to an antibiotic.
In addition, it was also concerned with the "modernization" of productive structures, through an ambitious program of "industrial reconversion". Obsolete or ruinous companies were closed and credits were given to companies to introduce the necessary technological improvements to make them more competitive, among other measures. The most affected sectors were the steel and shipbuilding industries, especially the large public companies inherited from Franco's regime. Not coincidentally, it was in these sectors where the most important conflicts took place, with a proliferation of clashes between workers and the forces of public order, the most serious being those of Sagunto. This program was accompanied by heavy investments in infrastructure ─ thanks mainly to the European funds that arrived after the entry into the EEC ─ which allowed Spain to equip itself with a network of highways and freeways and to start the construction of the first high-speed rail line between Madrid and Seville that started operations in 1992. The positive effects of the economic policy started to show after 1985, when the Spanish economy began a strong expansion that would last until 1992. However, during those years there was also an increase in speculative capital movements led by people linked to the world of finance who were looking for easy enrichment.
Pancreatic elastase;Feces-Pancreatic elastase;Clinical Biochemistry Laboratory; Adenovirus DNA PCR;Adenovirus DNA PCR - Feces; Clinical Microbiology Laboratory; "Hemoglobin;F";Feces-Blood; Clinical biochemistry laboratory; "Calprotectin;F";"Fecal Calprotectin;massfr."; Clinical biochemistry laboratory; Worms, eggs and cysts (microscopy of formalin-ether concentrate);Worms, eggs and cysts (microscopy of formalin-ether concentrate); Clinical Microbiology Laboratory; Larviculture (Strongyloides, hookworms);Larviculture (Strongyloides, hookworms); Clinical Microbiology Laboratory; Clostridioides difficile;Clostridioides difficile DNA/RNA (PCR quicktest); Clinical Microbiology Laboratory; Tarmpato e parasites;PCR (Tarmprotozoer); Clinical Microbiology Laboratory; Diarrhea investigation;Diarrhea investigation; Clinical Microbiology Laboratory; Alternative list Gastrointestinal stool and parasite tests The following analyses (Normal Order Name; Designation in the laboratory; Laboratory) can be performed on fecal samples.
=== Phase 3 === Fasedienol (Aloradine; AM-005; PH-94B; 4-androstadienol) – vomeropherine Soclenicant (BNC-210; IW-2143) – α7 nicotinic acetylcholine receptor negative allosteric modulator (abandoned after failed phase 3 trials. See [1].) VQW-765 (VQW765; AQW051; AQW-051; JQH481R778) – α7 nicotinic acetylcholine receptor partial agonist [2]
Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. It is an application of the basic science of cancer immunology (immuno-oncology) and a growing subspecialty of oncology. Cancer immunotherapy exploits the fact that cancer cells often have tumor antigens, molecules on their surface that can bind to antibody proteins or T-cell receptors, triggering an immune system response. The tumor antigens are often proteins or other macromolecules (e.g., carbohydrates). Normal antibodies bind to external pathogens, but the modified immunotherapy antibodies bind to the tumor antigens marking and identifying the cancer cells for the immune system to inhibit or kill. The clinical success of cancer immunotherapy is highly variable between different forms of cancer; for instance, certain subtypes of gastric cancer react well to the approach whereas immunotherapy is not effective for other subtypes. Major types of cancer immunotherapy include immune checkpoint inhibitors, which block inhibitory pathways such as PD-1/PD-L1 and CTLA-4 to enhance T cell activity against tumors. These therapies have shown effectiveness in treating cancers such as melanoma and lung cancer. Adoptive cell therapies, including chimeric antigen receptor (CAR) T cell therapy, involve modifying a patient's immune cells to recognize cancer-specific antigens. These therapies have been particularly effective in certain blood cancers.
Sources: en.wikipedia.org
=== Kazuko's family === Yasuko Tomita as Mine Hosoki, Kazuko's mother. Gaku Hosokawa as Hisao Hosoki, Kazuko's younger brother and later business associate. Erika Shumoto as Akiko Hosoki, Kazuko's sister. Miho Kanazawa as Sachiko Hosoki, Kazuko's sister.
While the main habitat of earthworms is in soil, they are not restricted to this habitat. The brandling worm Eisenia fetida lives in decaying plant matter and manure. Arctiostrotus vancouverensis from Vancouver Island and the Olympic Peninsula is generally found in decaying conifer logs. Aporrectodea limicola, Sparganophilus spp., and several others are found in mud in streams (riparian species). Some species are arboreal, some aquatic and some euryhaline (salt-water tolerant) and littoral (living on the sea-shore), e.g. Pontodrilus litoralis. Even in the soil species, special habitats, such as ultramafic soils derived from serpentine, have an earthworm fauna of their own, e.g. New Caledonian Acanthodrilidae. Vermicomposting of organic wastes is currently processed using the epigeic Eisenia fetida and Eisenia andrei which are particularly adapted to the consumption of fresh organic matter without deepening in the substrate (contrary to the anecis Lumbricus terrestris) and which tolerate the heat generated in compost heaps. Addition of this humified organic matter to the soil, preferably as a surface mulch, will improve moisture and nutrient availability, with beneficial effects on the soil microflora. It will also provide several species of earthworms with their food and nutrient requirements, and will create the optimum conditions of temperature and moisture that will stimulate their activity, although to a lesser extent than bacterial-mediated compost. Earthworms are environmental indicators of soil health.
=== Purine metabolism === GMP synthase is the second step in the generation of GMP from IMP; the first step occurs when IMP dehydrogenase generates XMP, and then GMP synthetase is able to react with glutamine and ATP to generate GMP. IMP may also be generated into AMP by adenylosuccinate synthetase and then adenylosuccinate lyase.
Through individualized research projects, trainees gain practical experience in study design, experimental methods, data analysis, scientific communication, and responsible conduct of research while developing an appreciation for interdisciplinary approaches to aging science. In addition to mentored research, UT-MSTAR offers a structured educational curriculum that includes seminars on aging biology, geriatrics, research ethics, biostatistics, grant writing, scientific presentations, and career development. Students also participate in clinical shadowing experiences with geriatricians and clinician-scientists, allowing them to observe the translation of aging research into patient care and better understand the complex medical, functional, and psychosocial needs of older adults. At the conclusion of the program, trainees present their research at the annual UT-MSTAR consortium meeting and are encouraged to present their work at national scientific conferences. The long-term objective of UT-MSTAR is to strengthen the national pipeline of physician-scientists dedicated to aging research by fostering sustained interest in geriatrics, geroscience, and translational research. Through individualized mentorship, multidisciplinary training, clinical exposure, and collaboration across four UT medical schools, the program equips future physicians with the scientific foundation, research skills, and professional networks needed to pursue careers focused on improving the healthspan, independence, and quality of life of older adults.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.